NDAINTRAVENOUSEMULSION
Approved
Aug 2008
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
CLEVIPREX (clevidipine) by Chiesi is calcium channel antagonists [moa]. Approved for dihydropyridine calcium channel blocker [epc]. First approved in 2008.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEVIPREX (clevidipine) is an intravenous dihydropyridine calcium channel blocker used for acute blood pressure reduction in perioperative settings. It works by antagonizing L-type calcium channels to produce rapid, titratable vasodilation. The drug is formulated as an oil-in-water emulsion for IV administration.
Peak4.9 years to LOE
Product is in peak commercialization phase with established market presence; team size likely stable with focus on market maintenance rather than expansion.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Started Jun 2024
1,018 enrolled
Intracerebral HemorrhageStrokeHypertension
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Started Jul 2023
378 enrolled
Hypertensive Emergency
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
Started Mar 2014
22 enrolled
Pediatric Perioperative Blood Pressure Management
Why This Matters for Your Career
Worked on CLEVIPREX at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.